184 related articles for article (PubMed ID: 8642503)
1. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K
J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
[TBL] [Abstract][Full Text] [Related]
2. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
Daniel WC; Meidell RS; Hillis LD; Lange RA
Coron Artery Dis; 1996 Jan; 7(1):45-9. PubMed ID: 8773432
[TBL] [Abstract][Full Text] [Related]
3. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
4. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
Sane DC; Stump DC; Topol EJ; Sigmon KN; Kereiakes DJ; George BS; Mantell SJ; Macy E; Collen D; Califf RM
Thromb Haemost; 1991 Mar; 65(3):275-9. PubMed ID: 1904653
[TBL] [Abstract][Full Text] [Related]
5. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
[TBL] [Abstract][Full Text] [Related]
6. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
Speidl WS; Nikfardjam M; Niessner A; Zeiner A; Jordanova N; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
Thromb Res; 2007; 119(3):331-6. PubMed ID: 16616324
[TBL] [Abstract][Full Text] [Related]
7. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
[TBL] [Abstract][Full Text] [Related]
8. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
[TBL] [Abstract][Full Text] [Related]
9. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
10. [t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction].
Yamada S; Yamada R; Ishii A; Ashikawa K; Nakamura M; Sasamata M; Watanabe S
Rinsho Byori; 1990 Jul; 38(7):819-24. PubMed ID: 2119465
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
12. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
13. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
Wallnöfer AE; van Griensven JM; Schoemaker HC; Cohen AF; Lambert W; Kluft C; Meijer P; Kooistra T
Thromb Haemost; 1993 Dec; 70(6):1005-8. PubMed ID: 8165591
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
15. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
Itakura H; Sobel BE; Boothroyd D; Leung LL; Iribarren C; Go AS; Fortmann SP; Quertermous T; Hlatky MA;
Am Heart J; 2007 Dec; 154(6):1059-64. PubMed ID: 18035075
[TBL] [Abstract][Full Text] [Related]
16. Changes in plasma levels of tissue plasminogen activator and its inhibitor in aged myocardial infarction patients.
Chen HZ; Jia HY; Song HY; Wang JY
Chin Med J (Engl); 1990 Jul; 103(7):541-5. PubMed ID: 2119970
[TBL] [Abstract][Full Text] [Related]
17. [A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease].
Chen ZY
Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Jun; 21(3):163-4, 188. PubMed ID: 8243232
[TBL] [Abstract][Full Text] [Related]
18. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
19. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
Hamsten A; Wiman B; de Faire U; Blombäck M
N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]